Vertex Prices Cystic Fibrosis Combo Treatment at $311,000-per-Year
By News
Published 5 years ago on
October 22, 2019
Share
[aggregation-styles]
Reuters
Reuters
(Reuters) – Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis (CF) at $311,503 per year, after winning early U.S. approval on Monday.
Shares of the drugmaker, which also raised its 2019 sales forecast for CF products, were up 3% in after-hours trading.
The U.S. Food and Drug Administration approval, which comes five months ahead of the agency’s previously announced action date, greatly expands the percentage of cystic fibrosis patients that Vertex can treat.
Shares of the drugmaker, which also raised its 2019 sales forecast for CF products, were up 3% in after-hours trading.
The U.S. Food and Drug Administration approval, which comes five months ahead of the agency’s previously announced action date, greatly expands the percentage of cystic fibrosis patients that Vertex can treat.
By Manojna Maddipatla and Carl O’Donnell | 22 Oct 2019
RELATED TOPICS:
Hamas Is Sending a Delegation to Egypt for Further Cease-Fire Talks in the Latest Sign of Progress
World /
15 hours ago
DEA’s Marijuana Reclassification Could Revive California’s Struggling Pot Industry
Cannabis /
15 hours ago
US Airstrike Targeting Al-Qaida Leader in Syria Killed a Farmer, American Military Says
World /
16 hours ago
Lagging Revenue Drives California Budget Deficit as Deadline Nears
Opinion /
17 hours ago
Latest
Videos
Animals /
57 mins ago
Meet Goldie Hawn: The Adorable Yorkie with a Heart of Gold
World /
15 hours ago
Hamas Is Sending a Delegation to Egypt for Further Cease-Fire Talks in the Latest Sign of Progress
Cannabis /
15 hours ago